Novavax rockets on news of COVID-19 vaccine deal with Sanofi – The Pharma Letter

French pharma major Sanofi (Euronext: SAN) says that, as part of its commitment to developing a diverse portfolio of best-in-class vaccines, it has entered into a co-exclusive licensing agreement with US biotech Novavax (Nasdaq: NVAX).

Shares of Novavax were up a 127.3% at $10.03 in pre-market trading this morning.

Sanofi is one of the worlds top producers of flu vaccines with sales of 2.7 billion euros ($2.9 billion) last year, but its early

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user pleaselogin. If your trial has come to an end, you cansubscribe here.

Try before you buy

All the news that moves the needle in pharma and biotech. Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. Daily roundup of key events in pharma and biotech. Monthly in-depth briefings on Boardroom appointments and M&A news. Choose from a cost-effective annual package or a flexible monthly subscription.

Follow this link:

Novavax rockets on news of COVID-19 vaccine deal with Sanofi - The Pharma Letter